Hybrid imaging PET/MR in prostatic carcinoma
Authors:
Jiří Ferda; Eva Ferdová; Radek Tupý; Jan Baxa
Authors place of work:
Klinika zobrazovacích metod LF UK a FN Plzeň
Published in the journal:
Čas. Lék. čes. 2018; 157: 169-174
Category:
Review Article
Summary
Imaging of the own prostatic tissue is being not easy using standard tumour imaging approaches, contrast enhanced computed tomography and the hybrid imaging using PET/CT with the application of the 18F-fluorodeoxyglucose. Magnetic resonance imaging is useful in detection of the patients with the elevated prostatic specific antigen (PSA) and/or with the increased index of the health prostate index (PHI).
The novel imaging possibilities of the imaging is hybrid positron emission tomography – magnetic resonance imaging (PET/MR) with the application of 18F-fluorocholine (FCH), 18F-natriumfluoride (18F-NaF) or 68Ga-PSMA-11 (ligand of prostatic specific membrane antigen) in detection, staging or restaging of the prostatic carcinoma. PET/MR represents current optimal method of the staging, restaging and therapy response evaluation of prostatic carcinoma.>
Keywords:
prostatic carcinoma, PET/MR, 18F-fluorocholine, 18F-natriumfluoride, 68Ga-PSMA-11
Zdroje
1. Eineluoto JT, Järvinen P, Kenttämies A et al. Repeat multiparametric MRI in prostate cancer patients on active surveillance. PLoS One 2017; 12(12): e0189272.
2. Brembilla G, Dell'Oglio P, Stabile A et al. Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. Eur Radiol 2018; 28(5): 1969–1976.
3. Kozlowski P, Chang SD, Jones EC, Goldenberg SL. Assessment of the need for DCE MRI in the detection of dominant lesions in the whole gland: Correlation between histology and MRI of prostate cancer. NMR Biomed 2018; 31(3).
4. Gaunay G, Patel V, Shah P et al. Role of multi-parametric MRI, of the prostate for screening and staging: Experience with over 1500 cases. Asian J Urol 2017; 4(1): 68–74.
5. Druskin SC, Tosoian JJ, Young A et al. Incorporating prostate health index density, mri, and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU Int 2018; 121(4): 619–626.
6. Mischinger J, Kaufmann S, Russo GI et al. Targeted versus systematic robot-assisted transperineal MRI-TRUS fusion prostate biopsy. BJU Int 2018; 121(5): 791–798.
7. Schmid DT, John H, Zweifel R et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235(2): 623–628.
8. Cimitan M, Bortolus R, Morassut S et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33(12): 1387–1398.
9. Kwee SA, Coel MN, Lim J. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging. Ann Nucl Med 2012; 26(6): 501–507.
10. Graute V, Jansen N, Ubleis C et al. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39(2): 271–282.
11. Kjölhede H, Ahlgren G, Almquist H et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012; 110(10): 1501–1506.
12. Umbehr MH, Müntener M, Hany T et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 2013; 64(1): 106–117
13. Dundee PE, Hutton AC, Eden CG. [18F]fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2011; 107(1): 158–159
14. Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a 68Ga-labeled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41(1): 11–20.
15. Beer AJ, Eiber M, Souvatzoglou M et al. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 2011; 12(2): 181–191.
16. Castellucci P, Picchio M. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 2013; 40(Suppl. 1): 36–40
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Hybrid imaging PET/MR in prostatic carcinoma
- Coronary CT angiography – current options and future perspectives in the diagnosis of coronary artery disease
- Contrast-enhanced ultrasonography
- Interventional radiology therapies for liver cancer